OPKO Health (OPK) shares tumbled 5.14% in intraday trading on Friday, as investors reacted to a significant downgrade from a major Wall Street firm. The biotechnology and diagnostics company's stock faced pressure after Jefferies lowered its rating and slashed its price target, signaling potential challenges ahead for the company.

Jefferies, a prominent investment bank and financial services company, downgraded OPKO Health from Buy to Hold, reflecting a more cautious stance on the stock's prospects. Additionally, the firm reduced its price target for OPKO Health to $1.60 from the previous $2.00, representing a 20% cut in their valuation outlook.

The downgrade and price target reduction appear to have sparked concern among investors, leading to the significant sell-off in OPKO Health's shares. As the market digests this new analyst perspective, it remains to be seen how OPKO Health will address these concerns and potentially regain investor confidence in the near term.